OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.62 USD
+0.01 (0.62%)
Updated Feb 6, 2025 04:00 PM ET
After-Market: $1.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.62 USD
+0.01 (0.62%)
Updated Feb 6, 2025 04:00 PM ET
After-Market: $1.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Zacks News
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.
OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains
by Zacks Equity Research
OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health (OPK) Q3 Earnings Surpass Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 130% and 4.26%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 9.33% and 3.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
by Zacks Equity Research
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
by Zacks Equity Research
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 88.89% and 1.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 100% and 0.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.
OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -33.33% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
by Zacks Equity Research
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
by Zacks Equity Research
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
by Zacks Equity Research
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for OPKO Health (OPK) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for OPKO Health (OPK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
IQVIA Holdings (IQV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 0.71% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Surges 7.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.